Rapid responses are electronic comments to the editor. They enable our users to debate issues raised in articles published on bmj.com. A rapid response is first posted online. If you need the URL (web address) of an individual response, simply click on the response headline and copy the URL from the browser window. A proportion of responses will, after editing, be published online and in the print journal as letters, which are indexed in PubMed. Rapid responses are not indexed in PubMed and they are not journal articles. The BMJ reserves the right to remove responses which are being wilfully misrepresented as published articles.
During the early days of using infliximab in rheumatoid arthritis (RA) it became apparent that patients with renal amyloidosis underwent a dramatic reduction in the amyloid load (1). Subsequeently research suggests that survival of RA patients with amyloid is substantially increased if biologics are employed (2). As the Biologics Register of the British Society for Rheumatology has a large cohort of patients treated with biologics it would be of interest to see whether such patients had a lower incidence of Alzheimer's than the control group. A negative finding would not necessarily be discouraging, if the biologic agents used in RA were shown not to pass the blood-brain barrier.
(1) Prof Gabriel Panayi, personal communication
(2) Kuroda T et al. Treatment with biologic agents improves the prognosis of patients with rheumatoid arthritis and amyloidosis. J Rheumatol. 2012 Jul;39(7):1348-54.